News & Events about Fibrogen Inc.
Study Did Not Meet Primary EndpointSAN FRANCISCO, May 05, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc.(NASDAQ: FGEN) today announced that MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with transfusion-dependent lower risk myelodysplastic syndromes (MDS) did not ...
Bassem Elmankabadi, M.D. joins Foresee Pharmaceuticals as a Senior Vice President of Clinical Development Bassem Elmankabadi, M.D. joins Foresee Pharmaceuticals as a Senior Vice President of Clinical Development PR Newswire TAIPEI, April 17, 2023 TAIPEI, April 17, 2023 /PRNewswire/ -- Foresee...
Globe Newswire
3 months ago
SAN FRANCISCO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Mark Eisner, M.D., M.P.H., Chief Medical Officer, will participate in a panel discussion at Cowens 43rd Annual Health Care Conference to be held in Boston on March 5 - 8, 2023. Details of the ...
Globe Newswire
3 months ago
SAN FRANCISCO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2022 financial results on Monday, February 27 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment ...